Medipal Holdings and JCR Pharma Sign Agreement to Develop Novel Treatment for GM2 Gangliosidosis Medipal Holdings and JCR Pharma have entered into a licensing agreement for overseas commercialization and joint development of JR-479 for GM2 gangliosidosis.

Medipal Holdings and JCR Pharma Sign Agreement to Develop Novel Treatment for GM2 Gangliosidosis #Japan #Tokyo #JCR_Pharma #Medipal_Holdings #GM2_Gangliosidosis

Strengthening GDPR Compliance: JCR Pharma's Partnership with Newton Consulting JCR Pharma enhances its GDPR compliance framework with the support of Newton Consulting, ensuring effective data protection across Europe.

Strengthening GDPR Compliance: JCR Pharma's Partnership with Newton Consulting #Japan #Tokyo #JCR_Pharma #Newton_Consulting #GDPR_Compliance